Enjoy 20% off your first order · use code Free shipping on orders $100+ · free 2-Day $175+Ships today when you order before 3 PM ET

Tissue ResearchNovember 9, 202611 min readCodex Research Team

BPC-157 vs TB-500: Structure and Research Differences

Explore products
CR
Codex Research TeamPublished November 9, 2026

11 min read12 cited sources15 FAQs

Two molecular models side by side: green spheres over a blood-vessel network on the left, blue spheres over actin filaments and a cell on the right
BPC-157 (left) is studied mainly in angiogenic signalling models; TB-500 (right) is studied for actin binding and cell migration.

BPC-157 and TB-500 are the two peptides most often mentioned together in tissue-repair research, but they come from unrelated proteins and are studied through different mechanisms. This guide compares them on structure, origin, research pathways, strength of evidence and testing.

Key takeaways

  • BPC-157 is a 15-residue peptide from a protein described in gastric juice. TB-500 is a 7-residue, N-acetylated fragment of thymosin beta-4, a protein found in most cells. They are not related.
  • In laboratory models, BPC-157 is studied mainly through growth-factor and angiogenic signalling, including VEGFR2-Akt-eNOS and FAK-paxillin. TB-500 is studied through actin binding, the cytoskeletal machinery cells use to move.
  • Most of the biological literature cited for TB-500 concerns full-length thymosin beta-4. Direct studies of the Ac-LKKTETQ fragment are far fewer, so the source molecule matters when reading research.
  • Much of the BPC-157 literature comes from a small number of research groups, largely in rodent models. Independent replication and human data are limited for both peptides.
  • Both are prohibited in sport under WADA section S0, neither is FDA approved, and both should come with a lot-matched COA confirming identity by mass spectrometry and purity by HPLC.
Important

Research use only. This comparison describes the structure of two research peptides and how they are studied in laboratory models. It does not describe human or animal use. Codex Research compounds are not approved by the FDA and are sold for in-vitro laboratory research only.

Quick answer

BPC-157 and TB-500 are unrelated peptides that are studied in overlapping research areas. BPC-157 is a fifteen-residue peptide derived from a protein described in gastric juice. TB-500 is a seven-residue, N-acetylated fragment of thymosin beta-4, a protein found in most cells of the body.

They are often mentioned together because both appear in tissue-repair and cell-migration research. But they are studied through different mechanisms: BPC-157 mainly through growth-factor and angiogenic signalling, such as the VEGFR2-Akt-eNOS pathway [2], and TB-500 mainly through actin binding, the cytoskeletal machinery cells use to move [6, 7]. The strength and source of the evidence also differ, which matters when reading the literature.

BPC-157 and TB-500 at a glance

BPC-157 TB-500
Sequence GEPPPGKPADDAGLV Ac-LKKTETQ
Length 15 amino acids 7 amino acids (N-acetylated)
Approximate molecular weight ~1,419 Da ~889 Da
Origin Partial sequence of a protein described in gastric juice Residues 17-23 of thymosin beta-4
Main research mechanism Angiogenic and growth-factor signalling Actin binding and cell migration
Key pathways in the literature VEGFR2-Akt-eNOS, FAK-paxillin, growth hormone receptor expression G-actin sequestration (parent protein), migration and angiogenesis models
Where most evidence comes from Rodent and cell-culture studies, concentrated in a few research groups Mostly full-length thymosin beta-4; fewer direct fragment studies
Current Codex purity 99.23% by RP-HPLC 99.06% by RP-HPLC
Regulatory status Not FDA approved; WADA S0 Not FDA approved; WADA S0

Where each peptide comes from

BPC-157: a fragment of a gastric protein

BPC stands for "body protection compound", the name given to a larger protein first described in human gastric juice. BPC-157 is a fifteen-amino-acid partial sequence of that protein, made synthetically for research [1, 4]. It is often described as a "stable gastric pentadecapeptide", because, unlike many peptides, it is reported to remain stable in acidic conditions, one reason it attracted so much laboratory interest.

There is no widely studied naturally circulating form of BPC-157 itself. Research uses the synthetic fifteen-residue sequence.

TB-500: a fragment of thymosin beta-4

Thymosin beta-4 (Tβ4) is a 43-amino-acid protein present in most cell types. Its best-characterized job is binding G-actin, the monomeric form of actin, and holding it in reserve [6]. When a cell moves or changes shape, it disassembles and rebuilds actin filaments, and Tβ4 helps manage the supply of building blocks. Mutational work mapped its actin-binding site to the region around residues 17 to 23 [7].

TB-500 is the name used for a synthetic peptide based on that region. When doping-control laboratories analysed products sold as TB-500, they identified the active content as Ac-LKKTETQ: residues 17 to 23 of Tβ4 with an acetyl group added to the N-terminus [8, 9]. The acetylation is not found in that position in the native protein's 17-23 segment; it is an artificial modification of the synthetic peptide.

Why the origins matter

The two peptides are not variants of each other, they do not share a sequence, and they do not act on the same target. Treating them as interchangeable "repair peptides" misses the main point of comparing them: they give researchers access to two different biological systems.

How BPC-157 is studied in the lab

Laboratory work on BPC-157 clusters around signalling pathways that control blood-vessel formation and cell migration.

Angiogenic signalling: VEGFR2-Akt-eNOS

A key mechanistic study examined BPC-157 in endothelial cell culture, the chick chorioallantoic membrane (CAM) assay and a rat hind-limb model. In human vascular endothelial cells it was associated with increased mRNA and protein expression of vascular endothelial growth factor receptor 2 (VEGFR2), though not of VEGF-A itself, together with VEGFR2 internalization and time-dependent activation of the VEGFR2-Akt-eNOS pathway [2]. Blocking endocytosis suppressed both the pathway activation and the increase in endothelial tube formation, which points to receptor internalization as part of the mechanism.

Fibroblast migration: FAK-paxillin

In tendon fibroblasts cultured from rat Achilles tendon, BPC-157 was reported to accelerate outgrowth from tendon explants and increase cell migration and spreading in a concentration-dependent way [1]. It did not directly change proliferation, but it improved cell survival under oxidative (H2O2) stress. The authors linked the migration effects to activation of the FAK-paxillin pathway, a central route by which cells sense and respond to their surroundings during movement.

Growth hormone receptor expression

A follow-up study from the same group reported that BPC-157 increased growth hormone receptor expression in tendon fibroblasts at both mRNA and protein level [3]. This is a third, separate line of evidence, and a reminder that BPC-157 has been associated with several signalling systems rather than one clean target.

The broader BPC-157 literature

Reviews describe a large body of rodent work across tendon, ligament, muscle, bone and gastrointestinal models [4, 5]. Two features of that literature are worth knowing:

  1. Concentration of authorship. A substantial share of published BPC-157 studies comes from a small number of research groups. Independent replication is the usual test of a finding, and for BPC-157 it is thinner than for many established compounds.
  2. Preclinical scope. The evidence is overwhelmingly from cell culture and animal models. Reviews themselves note the gap between this preclinical base and controlled human data [5].

How TB-500 is studied in the lab

Actin binding: the core mechanism

TB-500's sequence corresponds to the actin-binding region of Tβ4 [7]. The parent protein is described as the major actin-sequestering molecule in many eukaryotic cells [6], so the relevant research questions concern cytoskeletal dynamics: how cells regulate their pool of G-actin, extend leading edges and migrate. Typical in-vitro work includes actin-polymerization and G-actin binding assays and scratch-wound migration assays.

The parent protein carries most of the evidence

Much of the biological literature cited for TB-500 concerns full-length thymosin beta-4, not the seven-residue fragment. This is the biggest difference in how you should read the two bodies of research. Foundational work, for example, reported that Tβ4 increased re-epithelialization and was angiogenic in a rat full-thickness dermal model [10], and a broad review covers its roles in migration, angiogenesis and repair [6].

There is direct evidence that the actin-binding region carries some of that activity. One study reported that both Tβ4 and a synthetic peptide containing its actin-binding domain promoted dermal repair in two mouse models with slowed tissue repair [11]. But studies of the exact Ac-LKKTETQ molecule are far fewer than studies of the whole protein.

When you read a source about TB-500, check which molecule it describes. A finding about the 43-residue protein cannot automatically be transferred to the 7-residue fragment.

Analytical and doping-control work

A separate strand of TB-500 literature is analytical. Laboratories developed LC-MS methods to identify Ac-LKKTETQ and its metabolites in equine urine and plasma, because the product had appeared in horse racing [9], and confirmed the fragment's identity by synthesizing it and comparing it to seized material [8]. This work is useful to researchers for a different reason: it documents exactly what TB-500 is chemically, which helps when checking a certificate's identity line.

Mechanisms side by side

Question BPC-157 TB-500
What does it bind or act through? No single confirmed receptor; associated with VEGFR2, FAK-paxillin and GH receptor expression Actin-binding motif of thymosin beta-4
What cellular process is central? Growth-factor and angiogenic signalling Cytoskeletal reorganization and cell migration
Typical in-vitro assays Endothelial tube formation, transwell and scratch migration, Western blot for pathway activation Actin-polymerization and G-actin binding, scratch-wound migration, endothelial assays
Common model systems Tendon fibroblasts, endothelial cells, rodent models Keratinocytes, endothelial cells, rodent dermal models (mostly with Tβ4)

The two columns rarely overlap in mechanism, which is exactly why the peptides are compared. In a migration assay, for example, BPC-157 is studied for how it changes signalling upstream of movement, while TB-500 is studied for the actin machinery that executes it.

Evidence quality compared

Evidence feature BPC-157 TB-500
Volume of studies Large, mostly preclinical Large for thymosin beta-4; small for the fragment
Molecule studied The same 15-residue sequence sold for research Mostly the parent protein, not Ac-LKKTETQ
Independence of sources Concentrated in a few research groups Broader authorship for Tβ4
Controlled human data Very limited Very limited for the fragment
Analytical characterization Standard peptide methods Well documented through doping-control work

Neither peptide has the kind of evidence base that comes with an approved compound. Both are research chemicals, and their literature reads best as a set of laboratory hypotheses still being tested.

A short history of each name

Part of the confusion around these two peptides comes from their names, neither of which describes what the molecule is.

BPC-157 TB-500
What the name refers to "Body protection compound", plus a number used in the original research A product name, not a scientific designation
How the molecule is described in papers "Stable gastric pentadecapeptide BPC 157" "N-terminal acetylated 17-23 fragment of thymosin beta 4" or "Ac-LKKTETQ"
Where the name first appeared Research literature from the 1990s onward [4] Veterinary and commercial products, later characterized by doping-control labs [8, 9]
Alternative names BPC 157, PL 14736 in some studies Thymosin beta-4 fragment, Tβ4 (17-23)

As a result, searches and citations get mixed up. BPC-157 is at least a consistent name for one sequence. TB-500 has been used for more than one molecule, which is why this guide keeps returning to the identity line on the certificate.

Designing a study that compares the two

Because the peptides act through different systems, a well-designed comparison measures endpoints that can separate them. A few principles from general peptide research practice apply:

  1. Match the readout to the mechanism. Pathway assays such as Western blots for phosphorylated Akt, eNOS or FAK speak to BPC-157's reported signalling. Actin-polymerization and G-actin binding assays speak to TB-500's. A migration assay alone cannot tell the two apart.
  2. Compare on a molar basis, not by weight. BPC-157 is roughly 1.6 times the molecular weight of the TB-500 fragment, so equal masses contain different numbers of molecules. Expressing concentrations in molar units keeps comparisons fair.
  3. Run each peptide alone before combining them. If a study uses both together, or a blend such as Wolverine, single-peptide arms are what allow any effect to be attributed.
  4. Use the same lot throughout. Lot-to-lot differences in purity, counter-ion and peptide content can be larger than the effect being measured. A lot-matched certificate for each vial makes that traceable.
  5. Record the analytical data with the results. The lot number, purity and identity confirmation belong in the study record, so the material can be described exactly when results are reported.

None of this is specific to these two peptides, but the contrast between them makes it especially important. Two compounds that work through unrelated mechanisms can produce similar-looking results in a broad assay for completely different reasons.

Testing and identity: what to check on each COA

Because the two peptides are so different in size, mass spectrometry confirms identity easily, as long as the lab runs it.

Check BPC-157 TB-500
Expected mass by LC-MS ~1,419 Da ~889 Da (acetylated fragment)
Purity method RP-HPLC against a stated specification RP-HPLC against a stated specification
Current Codex lot KIZN072426 KIZN072426
Current Codex purity 99.23% 99.06%
Identity on current Codex COA Confirmed by LC-MS Confirmed by LC-MS

TB-500 deserves one extra check. Because some sources use the name for full-length thymosin beta-4, which weighs roughly 4.9 kDa, the observed mass on the identity line tells you which molecule you have. A result near 889 Da indicates the acetylated fragment; a result near 4.9 kDa indicates the full protein.

For both peptides, look for the lot number, an identity method, a purity method with a specification, an assay or potency figure, and contaminant results such as endotoxin. Our guides on third-party testing and HPLC vs mass spec explain each line, and what endotoxin testing means covers the most common contaminant test.

Stability and handling as research materials

Both peptides are supplied as lyophilized powder and are hygroscopic, so moisture, heat and light are the main storage risks for a sealed vial. Their chemistry differs in ways that matter for degradation:

  • BPC-157 contains two aspartic acid residues and several prolines. Aspartic acid is a known site for isomerization and backbone cleavage under some conditions.
  • TB-500 contains a C-terminal glutamine, which can undergo deamidation, and two lysines that can be sites of modification.

Neither vulnerability is unusual, and both are why stability studies and cold, dry storage matter. Our guide to peptides in transit, heat, cold and storage explains how temperature affects lyophilized material.

Regulatory status

Neither BPC-157 nor TB-500 is approved by the FDA for human or veterinary use. Both are research chemicals intended for in-vitro laboratory work, and Codex Research sells them on that basis only. See what research use only means for what that designation covers.

In sport, the World Anti-Doping Agency's Prohibited List includes section S0, which prohibits any pharmacological substance without current approval for human therapeutic use and names BPC-157 as an example [12]. TB-500 has been the subject of dedicated doping-control methods in equine racing [9].

Common misconceptions

"TB-500 is thymosin beta-4." It is a seven-residue fragment of it. Much of the cited research concerns the full protein.

"BPC-157 and TB-500 do the same thing." They come from unrelated proteins and are studied through different mechanisms, growth-factor signalling versus actin binding.

"BPC-157 has one known receptor." No single receptor has been confirmed. It has been associated with several pathways, including VEGFR2, FAK-paxillin and growth hormone receptor expression.

"A purity number confirms the compound." Purity by HPLC measures how much of the material is the main component, not what that component is. Identity needs mass spectrometry.

Blends that contain both

Because they are studied in complementary pathways, BPC-157 and TB-500 are often combined in research blends. Codex Research supplies three: Wolverine, which pairs the two; Glow, which adds GHK-Cu; and Klow, which adds GHK-Cu and KPV. Our Glow vs Klow comparison breaks down how those two blends differ. For attribution, many protocols run the single peptides alongside any blend.

What this comparison does not tell you

This guide describes structure, origin, the research literature and testing. It does not describe how either peptide behaves in any human or animal, establish safety or effectiveness for any purpose, or replace the certificate for the specific lot you hold. Research compounds are not approved by the FDA for human or veterinary use.

How Codex Research documents BPC-157 and TB-500

Every Codex BPC-157 and TB-500 lot ships with a lot-matched certificate of analysis from an independent laboratory, published on the product page, with identity by LC-MS, purity by RP-HPLC and contaminant testing. Match the lot number on the page to your vial before use. If you need the full report for a specific lot, contact info@codexresearch.shop. For a deeper look at one of the two, read What is BPC-157?.

Frequently asked questions

What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid peptide derived from a protein described in gastric juice. TB-500 is a 7-amino-acid, N-acetylated fragment of thymosin beta-4. They come from unrelated proteins and are studied through different mechanisms: BPC-157 mainly through growth-factor and angiogenic signalling, TB-500 mainly through actin binding and cell migration.
Is TB-500 the same as thymosin beta-4?
No, they are different molecules. Thymosin beta-4 is the full 43-residue protein, while TB-500 is the name used for a synthetic peptide based on its actin-binding region; analytical studies identified it as the N-acetylated sequence Ac-LKKTETQ, residues 17 to 23 of thymosin beta-4. Some sources use the names loosely, so the identity line on a COA is what confirms which molecule is present.
What is the sequence of BPC-157?
BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), fifteen amino acids with a molecular weight of about 1,419 Da.
What is the sequence of TB-500?
TB-500 is Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), seven amino acids with an acetylated N-terminus and a molecular weight of about 889 Da.
Which is larger, BPC-157 or TB-500?
BPC-157. It has fifteen residues and a molecular weight of about 1,419 Da, compared with seven residues and about 889 Da for the TB-500 fragment.
What pathways is BPC-157 studied in?
Laboratory work on BPC-157 centres on angiogenic and growth-factor signalling. Reported findings include activation of the VEGFR2-Akt-eNOS pathway in endothelial cells, FAK-paxillin activation and increased migration in tendon fibroblasts, and increased growth hormone receptor expression in tendon fibroblasts.
What pathways is TB-500 studied in?
TB-500 is studied for actin binding. Its sequence corresponds to the region of thymosin beta-4 that binds monomeric actin, the building block cells use to reorganize their cytoskeleton during migration. Work on the parent protein also covers angiogenesis and dermal repair models.
Why are BPC-157 and TB-500 often studied together?
Because they are studied in different parts of overlapping processes. In cell-migration and tissue-repair models, BPC-157 is associated with angiogenic and growth-factor signalling while TB-500 is associated with the actin machinery of cell movement, so researchers sometimes compare them side by side or in combination.
How strong is the research on each peptide?
Both rest mainly on preclinical work. Much of the BPC-157 literature comes from a small number of research groups, largely in rodent models. For TB-500, most biological studies concern full-length thymosin beta-4 rather than the fragment itself. Independent replication and human data are limited for both.
Are BPC-157 and TB-500 FDA approved?
No. The FDA has not approved either peptide for human or veterinary use. Codex Research sells both for in-vitro laboratory research only.
Are BPC-157 and TB-500 banned in sport?
Both fall under section S0 of the WADA Prohibited List, which covers pharmacological substances without approval for human therapeutic use and names BPC-157 as an example. TB-500 has also been the subject of doping-control methods in equine racing.
How do you confirm the identity of BPC-157 or TB-500?
By mass spectrometry, usually LC-MS. The measured mass should match the theoretical mass of the expected sequence: about 1,419 Da for BPC-157 and about 889 Da for the acetylated TB-500 fragment. HPLC alone measures purity, not identity.
What should a BPC-157 or TB-500 COA show?
A lot number matching the vial, identity by LC-MS, purity by RP-HPLC against a stated specification, an assay or potency figure, and contaminant results such as endotoxin, with the testing laboratory and report ID named.
Which blends contain both peptides?
Codex Research Wolverine, Glow and Klow all contain BPC-157 and TB-500. Glow adds GHK-Cu, and Klow adds GHK-Cu and KPV.
How should BPC-157 and TB-500 be stored as research materials?
Both are supplied as lyophilized powder. Sealed vials are stored cold, dry and protected from light, and the lot number is kept with the vial so it can be matched to its certificate.

References

  1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780.
  2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333.
  3. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077.
  4. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989.
  5. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.
  6. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429.
  7. Van Troys M, Dewitte D, Goethals M, et al. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J. 1996;15(2):201-210.
  8. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738.
  9. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69.
  10. Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
  11. Philp D, Badamchian M, Scheremeta B, et al. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24.
  12. World Anti-Doping Agency. The Prohibited List, section S0: Non-approved substances.
For research use only. This article summarizes published laboratory and preclinical literature for reference. It is not medical advice. Codex Research products are not FDA approved and are not for human or animal consumption or for any clinical or medical use.

Shop the lab

Popular research peptides

BPC-157Repair

Research peptide

BPC-157

Tissue-Repair Research

BPC-157 is a 15-amino-acid synthetic peptide taken from a gastric-juice protein, studied in endothelial, fibroblast and growth-factor research. Lot-tested by HPLC and LC-MS.

99%+Purity+149Reward pts
$59.99
View product
TB-500Repair

Research peptide

TB-500

Tissue-Repair Research

TB-500 is Ac-LKKTETQ, the acetylated actin-binding fragment of Thymosin Beta-4 (residues 17–23), supplied as a lyophilized peptide for actin-regulation and cell-migration research.

99%+Purity+187Reward pts
$74.99
View product
GHK-CuDermal

Research peptide

GHK-Cu

Dermal Matrix Research

GHK-Cu is the copper(II) complex of the tripeptide Gly-His-Lys, a constituent of human plasma, studied in fibroblast matrix and copper-transport research. Lot-tested by HPLC.

99%+Purity+99Reward pts
$39.99
View product
GlowBlends

Research peptide

Glow

Repair Blend

Glow is a three-peptide research blend: 49.87 mg GHK-Cu, 9.88 mg BPC-157 and 9.32 mg TB-500 per vial on the current lot, measured by HPLC and tested on a full safety panel.

99%+Purity+237Reward pts
$94.99
View product
NAD+Cellular

Research peptide

NAD+

Cellular Research

NAD+ is nicotinamide adenine dinucleotide, the oxidized redox coenzyme and sirtuin substrate, supplied as lyophilized powder in 500 mg and 1000 mg vials. Lot-tested by LC-MS.

99%+Purity+224Reward pts
$89.99
View product
KlowBlends

Research peptide

Klow

Repair Blend

Klow is a four-peptide research blend: 51.33 mg GHK-Cu, 11.55 mg KPV, 9.32 mg TB-500 and 8.00 mg BPC-157 per vial on the current lot, for multi-pathway laboratory research.

99%+Purity+249Reward pts
$99.99
View product
Melanotan IIDermal

Research peptide

Melanotan II

Melanocortin Research

Melanotan II is a cyclic lactam analog of alpha-MSH that binds the melanocortin receptors, lot-tested at 99.91% purity with a published certificate.

99%+Purity+112Reward pts
$44.99
View product
IpamorelinGH axis

Research peptide

Ipamorelin

GH-Axis Research

Ipamorelin is a five-residue synthetic peptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, studied as a selective agonist at the ghrelin receptor. Lot-tested by RP-HPLC.

99%+Purity+87Reward pts
$34.99
View product
SemaxNeuro

Research peptide

Semax

Neuropeptide Research

Semax is a seven-residue ACTH(4-7) analogue with a Pro-Gly-Pro tail, studied in BDNF, trkB and cholinergic-neuron research. 5 mg and 10 mg vials, lot-tested by LC-MS.

99%+Purity+124Reward pts
$49.99
View product
SelankNeuro

Research peptide

Selank

Neuropeptide Research

Selank is a seven-residue tuftsin analogue, Thr-Lys-Pro-Arg-Pro-Gly-Pro, studied in enkephalinase and neurotransmission gene-expression research. Lot-tested by LC-MS.

99%+Purity+112Reward pts
$44.99
View product

Keep reading

Purity & COAs
November 14, 2026

What a Peptide Certificate of Analysis Can't Tell You

A certificate of analysis reports the tests a lab ran on one sample on one date. This guide sets out eight things the page cannot tell you, from untested properties and method blind spots to storage after the test, and names the document that fills each gap.

Read Article
Purity & COAs
November 14, 2026

Matching a Peptide COA to Your Lot Number: What to Check

A certificate of analysis describes one lot. This guide shows which five fields tie a report to the vial in your hand, what the sample ID and received date mean, when one report can cover more than one vial size, and what to do when the lot numbers differ.

Read Article
Purity & COAs
November 14, 2026

How Are Peptides Made? Solid-Phase Synthesis Step by Step

Most synthetic peptides are built one amino acid at a time on a resin bead, a method called solid-phase peptide synthesis. This guide walks through each step, explains why a fraction of a percent of yield per step decides the quality of the result, shows where impurities come from, and follows the peptide from crude product to finished vial.

Read Article

From lab to your door

Every compound.Every lot, proven.

U.S.-made research vials, shipped with lot-matched, lab-tested COAs you can scan straight off the label.